REG - Graft Polymer (UK) - Business Update

Graft Polymer (UK)Announcement

07/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240607:nRSG4995Ra&default-theme=true

RNS Number : 4995R  Graft Polymer (UK) PLC  07 June 2024

7 June 2024

 

Graft Polymer (UK) Plc

(the "Company")

 

Update on Recent Developments

 

Graft Polymer (UK) Plc (LSE: GPL), an innovative developer of biopolymer drug
delivery systems aimed at enhancing the effectiveness of therapeutics for
biopharmaceutical companies, is pleased to provide an overview of recent
progress.

 

Operational Review

 

On 2 May 2023, the Company announced the initiation of an operational review.
The Company is pleased to report that the first phase of this review has
concluded. Moving forward, one focus area for the Company will be to seek
commercial opportunities for its patented self-nanoemulsifying drug delivery
systems (SNEDDS) platform, to enhance the bioavailability, pharmacokinetics,
and stability of biopharmaceutical companies' therapeutics.

 

Currently, the Company is evaluating a shortlist of five entities for
potential future commercial collaboration in this space.

 

Focus on the Healthcare Industry

 

On 3 May 2024, the Company disclosed the disposal of Graft Polymer d.o.o.,
allowing us to concentrate our attention and resources on our Graft Bio
division. The Directors believe this division holds significant potential due
to its intellectual property (IP), licensing agreements, and sales contracts.

 

Recent Patent Filings

 

The Company continues to develop its intellectual property portfolio,
supporting its focus on the healthcare industry clients and targeting
SNEDDS-related commercial collaboration opportunities. Recently, the Company
submitted two utility patent applications (provisional) to the United States
Patent and Trademark Office (USPTO) for using its SNEDDS platform in drug
delivery for substance use disorders and mental health treatment.

 

On 28 May 2024, the Company filed the first of these applications titled
"Composition and Methods for Substance Use Disorders (SUDS) using a
Self-Nanoemulsifying Drug Delivery System (SNEDDS)," covering the innovative
application of its SNEDDS platform to enhance the bioavailability,
pharmacokinetics, and stability of therapeutics used in treating substance use
disorders.

 

On 31 May 2024, the Company filed the second provisional patent titled
"Composition and Methods for Mental Health Disorders using a
Self-Nanoemulsifying Drug Delivery System (SNEDDS)," covering the innovative
application of our SNEDDS platform to enhance the bioavailability,
pharmacokinetics, and stability of therapeutics used in treating mental health
disorders such as Generalized Anxiety Disorder (GAD), Major Depressive
Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD).

 

Enquiries:

 

Graft Polymer (UK) Plc:

Anthony Tennyson, CEO and Executive Director: anthonytennyson@graftpolymer.com

Yifat Steuer, CFO and Executive Director: yifat@graftpolymer.com

 

Allenby Capital (Broker):

Phone: +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance)

Guy McDougall (Sales)

 

About Graft Polymer (UK) Plc

 

Graft Polymer (UK) Plc (LSE: GPL) is an innovative developer of biopolymer
drug delivery systems dedicated to assisting biopharmaceutical companies in
enhancing the effectiveness of their therapeutics. Our proprietary patented
platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS),
represents a cutting-edge solution in drug delivery technology. By integrating
active pharmaceutical ingredients (APIs) into our novel, patented delivery
systems, we enable clients to improve the bioavailability, pharmacokinetics,
and stability of their therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSSEEFMELSEEM